Artiva Biotherapeutics Inc
artivabio.comWhat Do They Do?
Develops donor-derived natural killer cell therapies for patients with autoimmune diseases and cancers, including AlloNK, a frozen cell treatment being tested with antibodies for autoimmune diseases.
10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from…View ↗
Our lead product candidate, AlloNK, is currently being evaluated in combination with B-cell targeted mAbs in patients with autoimmune…View ↗
Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell…View ↗
Who Are Their Customers?
Artiva is developing treatments for patients with autoimmune diseases and cancers. It supplies AlloNK and funding to a community rheumatology clinic running an investigator-initiated trial; it has not established commercial sales and distribution capabilities.
10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from…View ↗
In April 2024, the FDA cleared an IND submitted by Integral Rheumatology & Immunology Specialists (IRIS), a large community practice…View ↗
Sales and MarketingView ↗
We have incurred significant operating losses since the commencement of our operations. We have never generated any revenue from product…View ↗
How Are They Changing?
-
Aug 6, 2026
FDA granted RMAT designation for AlloNK in refractory rheumatoid arthritis
Artiva also plans to start a Phase 3 trial of AlloNK plus rituximab versus rituximab alone in the second half of 2026.
Sources
8-K, filed Aug 6, 2026
Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150…View ↗
-
May 19, 2026
The CFO departed and the CEO took over the principal finance roles
Thad Huston left as CFO, and Fred Aslan was appointed principal financial and accounting officer.
Sources
8-K, filed May 19, 2026
Departure of Chief Financial OfficerView ↗
Who Do They Compete With?
Competes with Adicet Bio, Allogene Therapeutics, Amgen, Artec Biotech, Autolus Therapeutics, Bristol-Myers Squibb, Cabaletta Bio, Capstan Therapeutics, Candid Therapeutics, Caribou Biosciences, Cartesian Therapeutics, Celularity, Century Therapeutics, Chimeric Therapeutics, Climb Bio, Coeptis Therapeutics Holdings, Cullinan Therapeutics, Deverra Therapeutics, Fate Therapeutics, and Gamida Cell
10-K for FY2025, filed Mar 10, 2026Our known biopharmaceutical competitors that are developing allogeneic NK, CAR-NK, or CAR-T cell therapies or T-cell engaging bispecific…View ↗
Loading...
